Altre lingue CANbridge Pharmaceuticals Inc.

Azioni

1228

KYG1821D1097

Mercato chiuso - Hong Kong S.E. Altri mercati azionari 10:08:42 28/06/2024			Variaz. 5gg	Var. 1 gen.
0,33 ^HKD	0,00%		0,00%	-66,67%

22/04	CANbridge Pharmaceuticals Inc. annuncia i risultati dello studio clinico di fase II CAN008 per il trattamento del glioblastoma multiforme	CI
28/03	CANbridge Pharmaceuticals Inc. riporta i risultati degli utili per l'intero anno conclusosi il 31 dicembre 2023	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Canbridge Pharmaceuticals Shelves Glioblastoma Drug After Phase II Clinical Trials	23/04
CANbridge Pharmaceuticals Inc. Announces Results of CAN008 Phase II Clinical Trial for the Treatment of Glioblastoma Multiforme	22/04
CANbridge Pharmaceuticals Inc. Announces Change of Principal Place of Business in Hong Kong, Effect from April 15, 2024	12/04
CANbridge Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
CANbridge and PUMCH announced the establishment of PUMCH, CANbridge Genetic Defect Rare Disease Innovation and Translation Base	04/03
CANbridge Pharmaceuticals Grants Share Options, Restricted Shares	08/02
CANbridge Pharmaceuticals Inc. Announces Resignation of Derek Paul Di Rocco as Non-Executive Director and A Member of the Nomination and Corporate Governance Committee	23/11
CANbridge Pharmaceuticals - Foundation consolidated over time and for a rosy future, 2023 China Conference on Rare Diseases closed successfully	07/11
CANbridge Pharmaceuticals to Present Fabry Disease Gene Therapy Abstract at ESGCT 30th Annual Congress	26/10/23
CANbridge Pharmaceuticals Inc. to Present Fabry Disease Gene Therapy Abstract At Esgct 30Th Annual Congress	25/10/23
CANbridge Announces NDA Acceptance of CAN108 for Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis by China's National Medical Products Administration	18/10/23
CANbridge Announces NDA Acceptance of CAN108 (®/LIVMARLI®) for Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis by China's National Medical Products Administration	17/10/23
CANbridge Announces Full Enrollment Reached in the Core Part of the CAN103 Phase 2 trial for Gaucher Disease in China	16/10/23
Canbridge Pharmaceuticals Inc. Announces Full Enrollment Reached in the Core Part of the Can103 Phase 2 Trial for Gaucher Disease in China	16/10/23
CANbridge Announces Marketing Approval of CAN108 in Taiwan for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome	09/10/23
Canbridge Pharmaceuticals Inc. Announces Marketing Approval of Can108 (Maralixibat Chloride Oral Solution /Livmarli®?) in Taiwan for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome	09/10/23
CANbridge to Participate in Two Investor Conferences in September	07/09/23
CANbridge Pharmaceuticals' H1 Attributable Loss Narrows	31/08/23
CANbridge Pharmaceuticals Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	31/08/23
CANbridge Pharmaceuticals Releases Phase 1B Data for Red Blood Cell Disorder Treatment	26/06/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue CANbridge Pharmaceuticals Inc.

Azioni

1228

KYG1821D1097

Altre lingue

Filtri